Whereas immunological profiling indicated that repeated dosing elicited enhanced anti-tumor immune responses, characterized by increased infiltration of CD3 + and CD8 + T cells into the TME and a concomitant reduction in PD-1 expression, highlighting the importance of the adaptive immune system in mediating therapeutic benefit. This evidence concerns the gene CD8A and neoplasm.